Comparison of benefits and harms
With screening
With no screening
Evidence quality
Events per 1000 people
Within 10 years
No important difference
The panel found that these differences were not important for most patients, because the intervention effects were negligible and/or very imprecise (such as statistically not significant)
No important difference
All cause mortality
Moderate
More
129
128
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
No serious concerns
Publication bias
No serious concerns
PSA screening probably has little or no effect on all cause mortality
No important difference
Prostate cancer mortality
Low
More
3
3
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
Serious
Publication bias
No serious concerns
PSA screening may have little or no effect on prostate cancer mortality
7 fewer
Incidence of cancer (any stage)
Low
More
32
39
Risk of Bias
Serious
Imprecision
Because of inconsistency
Indirectness
No serious concerns
Inconsistency
Serious
Publication bias
No serious concerns
PSA screening may increase the detection of prostate cancer (any stage)
7 fewer
Incidence of localized cancer
Low
More
19
26
Risk of Bias
Serious
Imprecision
Because of inconsistency
Indirectness
No serious concerns
Inconsistency
Serious
Publication bias
No serious concerns
PSA screening may increase the detection of localized cancer (stage I or II)
Incidence of advanced cancer
Low
More
13
11
No important difference
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
Serious
Publication bias
No serious concerns
PSA screening may have little or no effect on the detection of advanced cancer (stage III or IV)
Within 1 month
Fewer
Biopsy-related complications
Low
More
Among 1000 men with PSA screening, more presented with complications due to prostate biopsies:
Blood in semen: 94
Pain: 45
Fever: 1 9
Hospitalized for sepsis: 1
Blood in urine: 67
Because of uncertainty due to estimating likelihood along the diagnostic pathway
At any time
Fewer
Cancer treatment complications
Low
More
Among 1000 men with PSA screening, more presented with complications due to cancer treatment:
Erection not firm enough for intercourse: 25
Urinary incontinence: 3
Because of uncertainty due to estimating likelihood along the diagnostic pathway
See patient decision aids
Selected evidence at lower risk of bias
This section includes only data from the ERSPC trial, conducted in 162 243 participants in 9 European countries
With screening
With no screening
Evidence quality
Events per 1000 people
Within 10 years
No important difference
The panel found that these differences were not important for most patients, because the intervention effects were negligible and/or very imprecise (such as statistically not significant)
No important difference
Moderate
More
129
129
All cause mortality
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
No serious concerns
Publication bias
No serious concerns
PSA screening probably has little or no effect on all cause mortality
1 fewer
Moderate
More
3
2
Prostate cancer mortality
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
No serious concerns
Publication bias
No serious concerns
PSA screening probably leads to a small reduction in prostate cancer mortality
18 fewer
Moderate
More
32
50
Incidence of cancer (any stage)
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
No serious concerns
Publication bias
No serious concerns
PSA screening probably increases the detection of prostate cancer (any stage)
14 fewer
Moderate
More
19
33
Incidence of localized cancer
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
No serious concerns
Publication bias
No serious concerns
PSA screening probably increases the detection of localized cancer (stage I or II)
13
Moderate
More
3 fewer
10
Incidence of advanced cancer
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
No serious concerns
Publication bias
No serious concerns
PSA screening probably slightly decreases the detection of advanced cancer (stage III or IV)
Within 1 month
Low
More
Biopsy-related complications
Fewer
Among 1000 men with PSA screening, more presented with complications due to prostate biopsies:
Blood in semen: 94
Pain: 45
Fever: 1 9
Hospitalized for sepsis: 1
Blood in urine: 67
Because of uncertainty due to estimating likelihood along the diagnostic pathway
At any time
Low
More
Cancer treatment complications
Fewer
Among 1000 men with PSA screening, more presented with complications due to cancer treatment:
Erection not firm enough for intercourse: 25
Urinary incontinence: 3
Because of uncertainty due to estimating likelihood along the diagnostic pathway
See patient decision aids
Men with family history of prostate cancer
Family history defined positive if man’s father or at least one brother had been diagnosed with prostate cancer
With screening
With no screening
Evidence quality
Events per 1000 people
Within 10 years
No important difference
The panel found that these differences were not important for most patients, because the intervention effects were negligible and/or very imprecise (such as statistically not significant)
29 fewer
Incidence of cancer (any stage)
Moderate
More
50
79
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
No serious concerns
Publication bias
No serious concerns
PSA screening probably increases the detection of prostate cancer (any stage)
19 fewer
25
Incidence of localized cancer
Moderate
More
44
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
No serious concerns
Publication bias
No serious concerns
PSA screening probably increases the detection of localized cancer (stage I or II)
See patient decision aids
With screening
With no screening
Evidence quality
Events per 1000 people
Within 10 years
No important difference
The panel found that these differences were not important for most patients, because the intervention effects were negligible and/or very imprecise (such as statistically not significant)
Prostate cancer mortality
Moderate
More
7
1 fewer
6
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
No serious concerns
Publication bias
No serious concerns
PSA screening probably has little or no effect on prostate cancer mortality
29 fewer
Incidence of cancer (any stage)
Moderate
More
51
80
Risk of Bias
Serious
Imprecision
No serious concerns
Indirectness
No serious concerns
Inconsistency
No serious concerns
Publication bias
No serious concerns
PSA screening probably increases the detection of prostate cancer (any stage)
See patient decision aids
Men with these characteristics carry a higher incidence of prostate cancer, and could be at higher risk of dying of prostate cancer. It remains uncertain whether the impact of screening is similar in these higher risk men in comparison to men at lower risk.
Men at higher risks
There is considerable variability among men's values and preferences regarding prostate cancer screening. Men who place a high value in avoiding complications from biopsies and subsequent treatment are likely to decline screening. In contrast, men who place a higher value in even a small reduction of prostate cancer mortality may opt for screening. Higher risk patients may be more likely to seek screening because they may worry more about prostate cancer and want to rule out the diagnosis.
Values and preferences
LUTS symptoms like these are common complaints in adult men that can have a major impact on quality of life and substantial economic burden. The aetiology of LUTS is multifactorial, benign prostatic enlargement, due to hyperplasia, being the major cause. Evidence to date indicates that men with LUTS are at no higher risk of prostate cancer than men without LUTS.
Lower Urinary Tract Symptoms (LUTS)
Key practical issues
PSA testing is done with a regular blood sample
Usually taken through rectum guided by ultrasound
Takes about 5-10 minutes
Antibiotics given before procedure
Local anaesthesia or sedation given before procedure
May have to stop blood thinners before procedure
Screening
If biopsy is required
Slow stream
Sensation of incomplete emptying
Increased urinary frequency
Family history of prostate cancer
African descent
Poorer socio-economic groups
Rapid Response:
Re: Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
On 22nd September 2018 The BMJ carried an article on PSA screening.
It struck me forcibly that there was no mention of fPSA (Free to Total PSA testing)
I wrote to the consultant who literally saved my life in 2009, by requiring this test asking for his view on why he thought it was omitted from the article. He wrote that It is clear that free / total PSA has become redundant for some reason as there is almost no talk of it now. I have no idea why. I agree with your comments regarding its utility in the borderline PSA situation. A paper in ‘Urology’ (an American journal) at https://www.ncbi.nlm.nih.gov/pubmed/12670561 entitled Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL. clearly shows that there is benefit to this test. https://www.healthline.com/health/prostate-cancer-free-psa#purpose is also in accord with our thinking. There is also a very comprehensive article, (that I have glossed over as I have not had time to read in detail) at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1495603/
Knowing that I would have almost certainly died had this test not been performed, and surgery carried out, I wondered whether the writer of your article has any insights into why this was omitted. I wonder if the author might advise please - Kind regards
Louis Shakinovsky
Competing interests: No competing interests